Recent Updates
Recently added Catalysts

Glioblastoma: 6 biotech companies competing in the clinic

OncologyKnife fightData as of 2026-09-04

Competitors6in the clinic
Median market cap$432Muniverse median $1.20B
Allocated capital$3.0B$15.5B competing
Phase 3 or filed02 mid, 4 early
Pure plays1this indication only
Capital rank67/299crowding rank 28

Glioblastoma is one of the more crowded fields on the map: 6 companies in the clinic, ranking it 28th of 299 indications by competitor count. The median competitor is worth $432M, below the $1.20B median of the universe.

That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.

IBRX carries 56% of the $15.5B competing here, more than the other 5 companies combined.

$3.0B of allocated capital sits in Glioblastoma, 67th of 299 indications, and 1 of the 6 companies are pure plays that trade on this indication alone.

Companies developing drugs for Glioblastoma 6

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IBRXImmunityBioN-803Phase 22$8.7BNo12 31 Dec 2026
BDTXBlack Diamond Therapeuticssilevertinib monotherapyPhase 21$121MNo2 31 Dec 2026
ERASErascaERAS-801Phase 11$5.7BNo3 31 Dec 2026
VSTMVerastemAvutometinibPhase 12$723MNo8 31 Dec 2026
INOInovio PharmaceuticalsINO-5401Phase 12$141MYes1 30 Oct 2026
NTHINeOnc Technologies HoldingsPerillyl alcoholPhase 11$124MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IBRX holds 56% of the $15.5B competing in this indication.

Why Glioblastoma is a knife fight

Crowded and cheaply priced. Six or more competitors and a median company below the universe median.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Glioblastoma has 6 competitors and a median of $432M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated betNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedProstate Cancer6 companies · $2.7B · median $1.1BKnife fightBreast Cancer10 companies · $2.7B · median $288MKnife fightBladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontestedHER2 Positive Breast Cancer2 companies · $3.3B · median $10.2BConcentrated betMeningioma3 companies · $2.5B · median $14.7BConcentrated betRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated bet

Glioblastoma pipeline questions

Which biotech companies are developing drugs for Glioblastoma?

6 US-listed companies in the $100M to $20B market cap band run clinical programmes in Glioblastoma. The largest and most advanced are ImmunityBio (IBRX, N-803, Phase 2); Black Diamond Therapeutics (BDTX, silevertinib monotherapy, Phase 2); Erasca (ERAS, ERAS-801, Phase 1); Verastem (VSTM, Avutometinib, Phase 1); Inovio Pharmaceuticals (INO, INO-5401, Phase 1). The full list of 6 is in the table on this page.

How advanced is the Glioblastoma pipeline?

Of the 6 clinical-stage programmes in Glioblastoma, 0 are in Phase 3 or filed, 2 are in mid-stage development and 4 are in early-stage development.

Which company leads the Glioblastoma field?

IBRX is the largest developer in Glioblastoma, holding 56% of the $15.5B of market capitalisation competing in the indication. The median competitor is worth $432M.

When is the next Glioblastoma catalyst?

The next dated catalyst in Glioblastoma is INO on 30 Oct 2026. 6 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map